- Wu M, Akinleye A, Zhu X (2013) Novel agents
for chronic lymphocytic leukemia. J Hematol
Oncol 6:36 - Graf SA, Gopal AK (2016) Idelalisib for the
treatment of non-Hodgkin lymphoma. Expert
Opin Pharmacother 17:265–274 - Greenwell BI, Flowers CR, Blum KA et al
(2017) Clinical use of PI3K inhibitors in
B-cell lymphoid malignancies: today and
tomorrow. Expert Rev Anticancer Ther 17
(3):271–279. https://doi.org/10.1080/
14737140.2017.1285702 - Somoza JR, Koditek D, Villasen ̃or AG et al
(2015) Structural, biochemical, and biophysi-
cal characterization of idelalisib binding to
phosphoinositide 3-kinase δ. J Biol Chem
290:8439–8446 - Davis AM, Teague SJ, Kleywegt GJ (2003)
Application and limitations of X-ray crystallo-
graphic data in structure-based ligand and drug
design. Angew Chem Int Ed Engl
42:2718–2736 - Sastry GM, Adzhigirey M, Day T (2013) Pro-
tein and ligand preparation: parameters, proto-
cols, and influence on virtual screening
enrichments. J Comput Aided Mol Des
27:221–234- Blundell TL, Jhoti H, Abell C (2002) High-
throughput crystallography for lead discovery
in drug design. Nat Rev Drug Discov 1:45–54 - Moda TL, Torres LG, Carrara AE et al (2008)
PK/DB: database for pharmacokinetic proper-
ties and predictive in silico ADME models.
Bioinformatics 24:2270–2271 - Clark DE (2005) Computational prediction of
ADMET properties: recent developments and
future challenges. In: Dixon DA (ed) Annual
reports in computational chemistry, vol 1. Else-
vier, Amsterdam, pp 133–151 - Waterbeemd H, Gifford E (2003) ADMET in
silico modelling: towards prediction paradise?
Nat Rev Drug Discov 2:192–204 - Roberts BC, Mancera RL (2008) Ligandpro-
tein docking with water molecules. J Chem Inf
Model 48:397–408 - Kirchmair J, Spitzer GM, Liedl KR (2011)
Consideration of water and solvation effects in
virtual screening. In: Sotriffer C (ed) Virtual
screening: principles, challenges, and practical
guidelines. Wiley-VCH Verlag, Weinheim
50 Ricardo N. dos Santos et al.